DVAX beat EPS expectations by 16.82%
Feb 20, 2025, 11:31 PM
1.39%
What does DVAX do
Dynavax Technologies is a biopharmaceutical company based in Emeryville, California, specializing in vaccines and immuno-oncology therapeutics, including the HEPLISAV-B hepatitis B vaccine. The company is developing additional vaccines, including candidates for shingles and Tdap.
Dynavax Technologies (DVAX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Dynavax Technologies's actual EPS was $0.05, beating the estimate of $0.04 per share, resulting in a 16.82% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.